T. Rowe Price Associates
CRGX

T. Rowe Price Associates’s CARGO Therapeutics CRGX Stock Holding History

T. Rowe Price Associates’s Portfolio CRGX Stock Details CRGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-602,137
Closed -$2.48M – 3064
2025
Q2 		$2.48M Buy
602,137
+4,455
+0.7% +$19.1K ﹤0.01% 1553
2025
Q1 		$2.43M Sell
597,682
-1,838,489
-75% -$12.3M ﹤0.01% 1520
2024
Q4 		$35.1M Sell
2,436,171
-258,135
-10% -$4.68M ﹤0.01% 862
2024
Q3 		$49.7M Sell
2,694,306
-483,765
-15% -$8.65M 0.01% 755
2024
Q2 		$52.2M Buy
3,178,071
+84,724
+3% +$1.61M 0.01% 715
2024
Q1 		$69M Buy
3,093,347
+854,840
+38% +$20.3M 0.01% 630
2023
Q4 		$51.8M Buy
+2,238,507
New +$38M 0.01% 701

Other funds holding CRGX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

T. Rowe Price Associates's CRGX Position: Q3 2025 in Review

T. Rowe Price Associates sold out of CARGO Therapeutics (CRGX) in Q3 2025, closing a stake of 602,137 shares — an estimated $2.48M sold.

T. Rowe Price Associates first reported a position in CRGX in Q4 2023 and held it in 7 quarters. The position peaked at $69M in Q1 2024. 1 fund tracked by Wall St. Rank holds CRGX as of Q3 2025.

  • T. Rowe Price Associates reported no remaining CARGO Therapeutics position as of Q3 2025 after selling out during the quarter.
  • T. Rowe Price Associates sold 602,137 CARGO Therapeutics shares in Q3 2025, an estimated $2.48M.
  • T. Rowe Price Associates first reported a position in CARGO Therapeutics in Q4 2023 and held it in 7 quarters.
  • T. Rowe Price Associates's CARGO Therapeutics position peaked at $69M in Q1 2024.
  • 1 fund tracked by Wall St. Rank held CARGO Therapeutics as of Q3 2025.

Based on T. Rowe Price Associates's 13F filing for Q3 2025, filed 14 Nov 2025.